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Abstract 
Aim: To study the long term benefits, toxicity and survival rate in patients with neuroen-
docrine  tumors  receiving  multiple  cycles  of  high  activity  In-111  Pentetreotide  therapy. 
Moreover, our secondary aim was to evaluate the value of F-18 FDG PET-CT scan as 
prognostic indicator in this group of patients. 
Background: Neuroendocrine tumors are a heterogeneous group of malignancies which are 
usually metastatic at diagnosis. Standard chemotherapy in these patients is associated with 
appreciable adverse events and low effectiveness. Since 1990s, Peptide receptor radionuclide 
therapy (PRRT) with radio-labeled somatostatin analogues has been introduced as a new 
method of treatment in patients with unresectable and/or metastatic neuroendocrine tumors 
expressing high levels of Somatostatin receptors.  
Methods: 112 patients with progressive disseminated and unresectable neuroendocrine 
tumor (stage III and stage IV) were enrolled in a non-randomized trial in an out-patient setting. 
High activity In-111 Pentetreotide (500 mCi (18.5 GBq) per cycle) was administered as an 
intravenous infusion over 3 hours and repeated therapy cycles every 9-12 weeks in eligible 
patients up to maximum of 4 cycles. Response to therapy was evaluated by clinical imaging 
using the RECIST criteria, metabolic criteria and patient’s quality of life questionnaire. Do-
simetry  and  biodistribution  studies  were  also  performed.  Finally,  Kaplan-Meier  survival 
analysis was performed for patients followed for greater than 12 months. The relationship 
between  pretreatment  F-18  FDG  PET-CT  scan  status  and  survival  was  determined  by 
two-tailed Student’s t-test in 42 patients who underwent pre-therapy PET scans.  
Results: For an average of 25 (median 18.65) months following the therapy, patients were 
evaluated for any evidence of toxicity. No significant acute toxicity was observed in patients. 
Grade II or III hematological toxicity (7.6% of patients), liver toxicity (18.4%) and also grade I 
renal toxicity (6.1%) was observed in 92 evaluable patients. Radiological responses were 
evaluated for an average of 29 months following their last cycle of therapy and results were 
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analyzed by the RECIST criteria. Majority (85%) of patients had stable disease (SD), partial 
response (PR) rate was 7.5% and progressive disease (PD) was observed in 7.5% of patients. 
The average survival was 24.67 months after 2 cycles of therapy, 30.53 months after 3 cycles 
of therapy and 30.19 months after 4 cycles of therapy. Of the 42 patients who had pre-
treatment PET-CT imaging, 31 patients had positive F-18 FDG scans (SUV > 2.5) with an 
average survival time of 18.9 months (range 1.4-45.8 months) and 11 patients had negative 
F-18 FDG scans (SUV ≤ 2.5) with an average survival time of 31.8 months (range 7.4-42.9 
months). Survival times for FDG negative patients were significantly longer than those for 
FDG positive patients (p = 0.001 with 95% confidence).  
Conclusion: High activity In-111 therapy is a safe and effective therapy for patients with 
progressive disseminated neuroendocrine tumors. No major hematological, renal and hepatic 
toxicities were observed. There was an increase in survival time particularly in patients with 
lower degree of liver involvement as well as patients who received three or more cycles of 
therapy, as compared to historical data. Pre-treatment FDG status may be a predictor of 
survival following In-111 pentetreotide therapy. 
Key words: In-111 Pentetreotide therapy, neuroendocrine tumors, long term benefits, toxicity and 
survival rate, F-18 FDG PET/CT scan 
Introduction 
Neuroendocrine  tumors  (NET)  are  a  rare,  het-
erogeneous  group  of  malignancies1,2.  Typically,  this 
category of malignancies are difficult to diagnose and 
treat3. While surgery can sometimes provide a cura-
tive  treatment  for  patients  with  localized  disease, 
NETs  often  present  as  late  stage  tumors  with  ad-
vanced metastatic disease3, making surgical resection 
impossible.  Traditional  chemotherapy  and  radiation 
treatment regimens may not be beneficial for patients 
with disseminated NETs.  
A  common  feature  of  differentiated  NETs  is  a 
high  level  expression  of  somatostatin  receptors  on 
their cell surface. This feature has been exploited by 
the  use  of  radiolabeled  somatostain  analogues  as  a 
tool for diagnosis and treatment for NETs4. Scintig-
raphy with indium-111 labeled somatostatin analogue 
pentetreotide  is  a  common  method  of  detection  of 
somatostatin  receptor  positive  NETs.  Ga-68  labeled 
somatostatin  analogues  have  also  been  used  for 
PET-CT scan in these patients recently5. 
Indium-111 is a gamma emitter that also emits 
Auger and conversion electrons during its decay cy-
cle. These electrons emit high energy at close range 
and are capable of inducing cytotoxic DNA damage6. 
Peptide receptor radionuclide therapy (PRRT) using 
somatostatin  analogues  labeled  with  high  activity 
In-111  pentetreotide  has  been  reported  to  be  a  safe 
and effective therapy for NETs7, 8.  
The first clinical trial of In-111 pentetreotide for 
the treatment of NETs was performed by Krenning et 
al.7 in Netherlands in 1994. Preliminary data from this 
study demonstrated the safety of repeated treatments 
with 90–180 mCi (3.3-6.6 GBq) of In-111 pentetreotide 
administered every 3 weeks for 10 cycles. In this ini-
tial study, response correlated with receptor expres-
sion.  Subsequent  studies  conducted  by  the  same 
group  confirmed  these  preliminary  findings8.  Like-
wise, additional investigational studies have reported 
significant  responses  to  high-activity  In-111           
pentetreotide  therapy  (180–500  mCi  (6.6-18.5  GBq) 
/treatment)  with  limited  toxicity7-15.  These  studies 
vary in patient selection, dosing, total activity admin-
istered, and reported outcomes, but all show signifi-
cant benefits and safety of In-111 pentetreotide ther-
apy. 
Generally, studies using higher activity of In-111 
(180–500 mCi (6.6-18.5 GBq)) report a greater impact 
on disease stabilization than those using lower activ-
ity  while  still  not  reaching  the  maximum-tolerated 
dose (MTD). We previously reported the safety and 
efficacy of high activity In-111 pentetreotide therapy 
in 32 patients who were treated with one or two cycles 
of 500 mCi (18.5 GBq) activity. The majority of these 
patients  demonstrated  disease  stabilization  and 
symptomatic  improvement,  with  minimal  hemato-
logic toxicity. No evidence of long-term renal toxicity 
was reported in patients who were followed for an 
average of 12 months16.  
Here, we report on the long-term safety and ef-
ficacy of high-activity In-111 pentetreotide in 112 pa-
tients who received one, two, three or four cycles of 
500  mCi  (18.5  GBq)  of  In-111  pentetreotide  therapy 
between Aug 2005 and July 2011.  
Materials and Methods 
Patient selection and enrollment 
Patients  diagnosed  with  histopathologically Theranostics 2012, 2(5) 
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confirmed  progressive  NETs  were  enrolled  in 
non-randomized trial to evaluate the safety and effi-
cacy of high-dose In-111 pentetreotide therapy in an 
out-patient setting. This study was performed under 
approval  from  the  institutional  review  board  at  St. 
Luke’s Episcopal hospital, a Baylor College of Medi-
cine affiliated hospital in Texas Medical Center and 
under an investigational new drug (IND) application 
from the United States Food and Drug Administration 
(FDA).  All  patients  gave  informed  consent  prior  to 
treatment.  
All  patients  demonstrated  disease  progression 
and had failed routine standard therapy prior to en-
rollment  in  the  current  study.  The  patients  had 
Karnofsky performance status of higher than 60. The 
patients  had  well  differentiated  neuroendocrine  tu-
mors  with or without  multiple liver  metastases. In-
clusion criteria required patients to demonstrate his-
topathological  confirmation  of  NETs  and  positive 
somatostatin  receptor  scintigraphy.  Tumor  markers 
and  function  were  included  for  diagnosis,  such  as 
chromogranin  A,  serotonin,  pancreastatin,  gastrin, 
Neurokinin  A,  pancreatic  polypeptide  nor-
metanephrine, alkaline phosphatase (ALP), and 24-h 
urine  5-hydroxyindole  acetic  acid  (5-HIAA).  All  in-
cluded  patients  had  a  positive  OctreoScan  with  an 
uptake grading equal to or exceeding 3 in a 4-point 
graded scale, also known as Krenning score.  
Preparation of High dose In-111 pentetreotide 
High dose In-111 pentetreotide was prepared as 
previously described15. Indium-111 chloride (111InCl3) 
was  purchased  from  MDS  Nordion  (Ottawa,  ON, 
Canada), and purified prior to radiolabeling by IsoTex 
Diagnostics, Inc. (Friendswood, TX). The synthesis of 
a  therapeutic  dose  of  In-111  pentetreotide  was  ob-
tained by adding ultra-pure  111InCl3 (~500 mCi (18.5 
GBq))  to  3  standard  kits  of  commercially  available 
Pentetreotide under aseptic conditions. 30µg peptide 
is used for each therapy. 
Treatment Protocol 
Patients were injected with In-111 pentetreotide 
as an intravenous infusion in physiological saline us-
ing  a  specially  designed,  lead  lined  IV  pole  to  de-
crease radiation exposure to the personnel. The infu-
sion  duration  was  approximately  3  hours,  and  was 
performed  in  an  outpatient  setting.  No  amino  acid 
infusion was administered before or after the therapy. 
Patients were evaluated for adverse events immedi-
ately following the therapy and hematological, renal 
and  hepatic  toxicities  using  NCI  common  toxicity 
criteria  on  week  4,  5,  6,  and  7  after  each  cycle  of 
treatment, and every three months thereafter. Patients 
were eligible for 2nd and 3rd therapy cycles 9-12 weeks 
after treatment. The 4th treatment was given approx-
imately 6 months after the third cycle. These patients 
were evaluated for a clinical and metabolic response 
prior to each cycle of therapy by interview, comple-
tion  of  quality  of  life  questionnaire  and  imaging 
studies, such as CT scan, MRI, Octreoscan and F-18 
FDG PET-CT scan. 
Dosimetry and biodistribution of In-111 pen-
tetreotide 
In-111 pentetreotide scintigraphy for dosimetry, 
visualization of tumor spread and assessment of ra-
dionuclide uptake intensity was performed. Patients 
were injected intravenously with 5 to 6 mCi (185-222 
MBq) of 111In-pentetreotide (Mallinckrodt Medical, St. 
Luis, MO-USA). Static anterior–posterior images were 
collected,  and  a  single-photon  emission  computed 
tomography (SPECT) study was carried out over the 
regions of tumor using a dual detector gamma scin-
tillation  SPECT  camera  equipped  with  a  medi-
um-energy  general  purpose  collimator  (Siemens 
E-cam).  For  each  patient,  whole-body  images  were 
performed 10 minutes after injection (before voiding), 
and at 2, 4, 24, and 48 hours. Regions of interest (ROI) 
were drawn around the major organs: liver, spleen, 
kidneys, urinary bladder and whole-body. The data 
points  representing  the  percentage  injected  dose 
(%ID/organ)  were  then  created  and  fitted  to  a 
mono-exponential,  bio-exponential,  or  an  up-
take/clearance curve. After curve fitting and integra-
tion,  the  cumulative  activity  and  residence  time  (t) 
was calculated for each organ. The femur curve was 
used to estimate the cumulative activity in the bone 
marrow. The radiation absorbed dose was calculated 
by entering the corresponding residence time into the 
OLINDA  software  program17,  which  computed  the 
radiation-absorbed  dose  values  as  mGy/MBq  or 
(rad/mCi) for each of the target organs.  
Statistical analysis 
Kaplan-Meier  survival  analysis,  Log-rank  and 
Wilcoxon  tests  were  performed  using  Graph-pad 
Prism 5 software (Graph Pad Software, Inc. La Jolla, 
CA). All survival times were calculated from the date 
of the first treatment.  
RESULTS 
One hundred and twelve patients (68 male, 44 
female)  with  somatostatin  receptor  positive  NETs 
underwent  treatment  with  high  activity  (500  mCi 
(18.5 GBq)) In-111 pentetreotide. Of these, 26 patients 
were treated with one cycle of therapy with an aver-
age dose of 490.6 mCi (18.15 GBq), (range 390-503 mCi Theranostics 2012, 2(5) 
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(14.43-18.61 GBq)). Fifty patients received two cycles 
of therapy with an average dose of 976.6 mCi (36134.2 
MBq)/patient (range 893-1012 mCi (33-37.4 GBq)) and 
28 patients received three cycles of therapy with an 
average dose of 1461.5 mCi (54 GBq)/patient (range 
1419-1495 mCi (52.5-55.3 GBq)). Finally, eight patients 
received four cycles of therapy with average dose of 
1950.5  mCi  (72.17  GBq)/patient  (1888-2022.54  mCi 
(69.9-74.8  GBq)).  Patient  who  received  one  cycle  of 
therapy  had  an  average  dose  to  kidney  of  334  rad 
(range 134-712 rad). Patients who received two cycles 
of  therapy  had  a  cumulative  renal  dose  of  563  rad 
(range  63-578  rad)  and  patients  who  received  three 
treatments  had  a  cumulative  renal  dose  of  654  rad 
(range 329-2273 rad) and patients who received the 
four cycles had cumulative average renal dose of 1132 
rad  (550-1987  rad).  Ninty-six  patients  (85.7%)  had 
gastroenteropancreatic  neuroendocrine  tumor 
(GEP-NET) cancer (67 patients (59.8%) with carcinoid 
cancer and 29 (25.8%) with pancreatic NET), 5 patients 
(4.4%)  had  pulmonary  NET,  4  patients  (3.6%)  had 
thymic  NET,  and  the  rest  of  7  patients  (6.2%)  had 
other subtypes of neuroendocrine cancer. No signifi-
cant  acute  toxicity  was  observed  immediately  fol-
lowing treatment and no patients required supportive 
treatment during therapy. Eleven patients (9.8%) had 
skin rash after treatment and 12 patients (10.7%) had 
mild to moderate nausea/vomiting after their treat-
ment. 
Patients were evaluated for evidence of toxicity 
using NCI common toxicity criteria and followed for 
an average of 25 months (1.2-56 months, median 18.65 
months). Of 92 evaluable patients, 7 patients (7.6%) 
had grade 2 or 3 hematological toxicity, which did not 
require supportive therapy. Duration of hematologi-
cal toxicities was 3 weeks (range 1-6 weeks). Grade 2 
or 3 liver toxicity was observed in 17 patients (18.4%). 
Patients  with  neuroendocrine  liver  metastases  who 
had abnormal  liver enzymes and alkaline phospha-
tase (ALP) levels prior to therapy did not show any 
significant  worsening  as  a  result  of  the  therapy.  In 
addition,  5  patients  (6.1%)  had  renal  toxicity  grade 
one. Of these patients, 1 patient had received 1 cycle 
of therapy, 2 patients had received 2 therapies and 2 
patients had received 3 therapies. No significant renal 
toxicity  was  observed  and  there  was  no  correlation 
between  renal  toxicity  and  cumulative  dose  to  the 
kidneys.  
Radiological response was initially assessed in 80 
evaluable  patients  for  an  average  of  29  months 
(1.26-60.2 months) following their last therapy. Anal-
ysis  was  using  the  Response  Evaluation  Criteria  in 
Solid Tumors criteria (RECIST criteria). A partial ra-
diological response was observed in 6 patients (7.5%). 
Stable disease was observed in 68 patients (85%). The 
remaining 6 (7.5%) patients had progressive disease.  
Hormonal response was assessed in 36 evaluable 
patients who received three or four cycles of therapy. 
A  biochemical  response  (>25%  reduction  from  pre-
treatment levels in at least one of the markers (Chro-
mogranin A, Serotonin, 5-HIAA)) was observed in 12 
patients (33%). 32% of patients had increased levels of 
all  hormonal  markers  when  compared  to 
pre-treatment levels. Statistically, there is no signifi-
cant  difference  in  tumor  marker  (Chromogranin  A, 
Serotonin) levels before and after the therapy assays. 
Kaplan-Meier  survival  analysis  was  conducted 
on patients who received 2 or more therapies (Fig. 1).  
 
 
Figure 1. Kaplan- Meier survival analysis of neuroendocrine tumor (NET) patients who received one, two, three or four cycles of high 
activity In-111 pentetreotide therapy. 
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The average survival was 24.67 months (after 2 
cycles  of  therapy,  4.97-65.4  months),  30.53  months 
(after 3 cycles of therapy, 8.83-68.6 months) and 30.19 
months (after 4 cycles of therapy, 16.87-56.07 months) 
(Wilcoxon Test, P < 0.05, 95% CI 0.5424 to 1.742). Two 
patients with GEP-NET became eligible for curative 
surgery and both are still alive (24.8 months and 27.37 
months  following  the  beginning  of  therapy).  There 
was no difference between men and women, or ethnic 
groups.  Kaplan-Meier  analysis  of  survival  rates 
among tumor types revealed that patients with islet 
cell  tumors  had  significantly  longer  survival  times 
compared to those with carcinoid tumors (Wilcoxon 
Test, P <0.05, 95% CI -0.05838 to 0.8546). Median sur-
vival  for  patients  with  islet  cell  tumors  was  40.77 
months compared with median survival time of 16.23 
months for patients with carcinoid tumors. There was 
no significant difference in survival between patients 
who had unresectable primary tumor with no identi-
fiable metastatic lesions (n = 11, median survival 33.1 
months (range 5.40 to 47.3 months)) and metastasis at 
one site (bone, lung or liver; n= 52 median survival 
24.6 months (range 8.97 to 54.9 months)). However, 
survival of patients who had multiple metastatic sties 
(lung and liver or bone and lung) was significantly 
decreased compared to those who had metastasis only 
at  one  site  (P  <  0.01,  Gehan-Breslow-Wilcoxon  test, 
95% CI 0.9635-2.215,). Median survival for this group 
was 16.78 months (range 2.3 to 43.77 months). Aver-
age  survival  of  6  patients  with  progressive  disease 
was 25.96 months (10.3-62.37 months). 
In order to clarify whether there is any correla-
tion  between disease burden and survival  time,  we 
studied the abdominal CT scan or MRI of 80 evaluable 
patients who had received at least 2 cycles of therapy 
and based on the extent of the liver involvement we 
subcategorized the patients into low bulk, with less 
than  50%  liver  involvement,  and  high  bulk,  with 
higher than 50% liver involvement. We realized that 
average survival time of patients (n= 40) with high 
liver involvement after two cycles of therapy is 21.96 
months.  However,  average  survival  rate  in  patients 
(n=40)  with  lower  liver  burden  is  28.3  months 
(Log-rank test P = 0.0805, 95% CI). Similarly, the sur-
vival of patients with less liver involvement who re-
ceived three or four cycles of therapy is higher, alt-
hough  not  statistically  significantly,  than  patients 
with  high liver burden (P = 0.2754  and P = 0.2210, 
respectively with 95% CI). These findings suggest that 
among  the  patients  who  have  received  the  same 
number of therapy cycles, patients with lower liver 
burden  live  longer  than  high  bulk  group,  although 
this  difference  is  not  statistically  significant.  Im-
portantly,  patients  who  received  higher  number  of 
therapy could live longer. 
Of  the  42  patients  who  had  pretreatment  PET 
imaging, 31 patients had positive FDG scans (SUV > 
2.5)  with  an  average  survival  time  of  18.9  months 
(range 1.4- 45.8 months) and 11 patients had negative 
FDG scans (SUV ≤ 2.5) with an average survival time 
of  31.8  months  (range  7.4-  42.9  months).  Survival 
times  for  FDG  negative  patients  were  significantly 
longer than those for FDG positive patients (P = 0.001 
with 95% confidence).  
All  patients  were  asked  to  complete  the  func-
tional Living Index questionnaire to assess and com-
pare the quality of life before and after their last cycle 
of therapy. In patients who received 2 or more cycles 
of  In-111  pentetreotide  therapy  data  showed  im-
provement in social, family, emotional and functional 
aspects of patient life, particularly following 3 cycles 
of In-111 PRRT therapy. 
DISCUSSION  
Neuroendocrine tumors are a rare, heterogene-
ous group of malignancies and the incidence of this 
cancer has significantly increased over the past three 
decades1,  2.  Typically,  these  cancers  are  difficult  to 
diagnose  and  treat3.  While  surgery  can  sometimes 
provide a curative treatment for patients with local-
ized disease, NETs often present as late stage tumors 
with advanced metastatic disease3. 
A  common  feature  of  differentiated  NETs  is  a 
high  level  expression  of  somatostatin  receptors  on 
their cell surface. This feature has been exploited by 
the use of radio-labeled somatostatin analogues as a 
tool for diagnosis and treatment for NETS4. 
Peptide  receptor  radionuclide  therapy  (PRRT) 
using  different  radiolabeled  somatostatin  analogues 
such as In-111 DTPA-Octreotide, Lu-177 DOTATATE 
and Y-90 DOTATOC have been used for the treatment 
of  disseminated  well  differentiated  neuroendocrine 
cancers.  
The first clinical trial of In-111 pentetreotide for 
the treatment of NETs was performed by Krenning et 
al.7 in Netherlands in 1994. Preliminary data from this 
study demonstrated the safety of repeated treatments 
with 90–180 mCi (3.3-6.6 GBq) of In-111 pentetreotide 
administered every 3 weeks for 10 cycles. In this ini-
tial study, response correlated with receptor expres-
sion.  Subsequent  studies  conducted  by  the  same 
group  confirmed  these  preliminary  findings8.  Like-
wise, additional investigational studies have reported 
significant  responses  to  high-activity  In-111  pen-
tetreotide  therapy  (180–500  mCi  (6.6-18.5 
GBq)/treatment) with limited toxicity7-15. These stud-
ies vary in patient selection, dosing, total activity ad-
ministered, and reported outcomes, but all show sig-Theranostics 2012, 2(5) 
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nificant  benefits  and  safety  of  In-111  pentetreotide 
therapy. 
Previously, in a study performed on 26 patients, 
Anthony et al18 reported SD in 81% of patients along 
with CR + PR equals to 8%, and 12% of the patients 
showed  progression.  In  their  study,  62%  of  the  pa-
tients  experienced  symptomatic  relief  or  improve-
ment and median survival was 18 months. Similarly, 
our  prior  study16 performed  on  18  patients  showed 
clinical  response  in  84%  of  the  patients,  CR  +  PR 
equals to 11% and median survival rate as high as 13.3 
months.  The  results  of  our  current  study  are  con-
sistent with these findings.  
Another radiolabeled somatostatin analog that is 
used for PRRT is Y-90 DOTATOC. Various phase 1 
and phase 2 PRRT trials have been performed with 
this  compound17.  Waldherr  et  al  20,  21,  22  performed 
several studies using Y-90 DOTATOC in populations 
of  patients  with  neuroendocrine  cancer.  Data  from 
Y-90  DOTATOC  studies  showed  CR  +  PR  rates  as 
high as 24%20, 21 and 33%22. However, similar to the 
data from Anthony et al.18, progressive disease was 
seen in 11%20, 21 and 9%22 of patients.  
In  another  study,  Kwekkeboom  and  his  col-
leagues23  administered  Lu-177  DOTATATE  for 
treatment of 310 patients with neuroendocrine cancer. 
The data showed CR + PR in 29% of patients. By in-
cluding  patients  with  minor  response  (MR),  this 
number increased to 45%. Stable disease was reported 
in 35% of cases.  
It is generally accepted that stable disease is the 
predominant response seen after In-111 pentetreotide 
therapy16, 18; although stable disease is still the com-
mon outcome after Y-9020, 21, 22 or Lu-17723, 28, 29 thera-
pies,  however,  partial  response  rate  is  generally 
higher  after  Y-90  or  Lu-177  radionuclide  therapies. 
Nonetheless, in order to study the toxicity profile of 
patients and to compare the efficacy of each therapy, a 
randomized clinical trial is needed. 
Lu-177 DOTATATE therapies using 4 cycles of 
200  mCi  (7.4  GBq)  Lu-177  DOTATATE  and  Y-90 
DOTATOC using maximum 6 GBq (160 mCi )/m28 or 
7.4 GBq (200 mCi )/m29 in four cycles produce more 
cases of PR and CR with requirement of protection of 
the kidneys using amino acid infusion. Hematological 
and nephrotoxicity appears to be more common fol-
lowing these therapies while it is rare with In-111 Oc-
treotide therapy. 
Recently attempts to improve response to PRRT 
have included tandem treatments with different radi-
olabeled  analogues.  A  response  to  Lu-177 
DOTATATE  therapy  was  observed  in  patients  who 
had  previously  undergone  previous  treatment  with 
Y-90 DOTATOC. No additional hematological or re-
nal toxicity was observed. Clinical response to Y-90 
DOTATOC  was  predictive  of  response  to  Lu-177 
DOTATATE24.   Retrospective  analysis  of  patients 
who received up to three cycles of Lu-177 Octreotate 
following  high  dose  In-111  Pentetreotide  therapy 
showed no significant increase in toxicity25, although 
the effect of tandem therapies on long-term progres-
sion  free  survival  remains  unclear.  As  we  reported 
before16, due to different peneteration range in tissue, 
In-111, Y-90 and Lu-177 behave differently once in-
troduced into the tissues. In-111 emits Auger electrons 
and  γ-rays.  The  Auger  electrons  have  a  maximum 
penetration range in tissue of 10 μm. In comparison, 
Y-90 is a pure β-emitter with a maximum penetration 
range in tissue of 12 mm and 177Lu is a β-emitter with 
a maximum particle range in tissue of 2 mm. Lu-177 
also emits γ-rays, which allows imaging and dosime-
try.  These  differences  in  particle  range  may  have 
therapeutic  advantages  as  patients  usually  have  tu-
mors of various sizes.  
Additionally, radiosensitizers have been used to 
improve response to PRRT. The addition of Capecita-
bine or 5-FU to PRRT has shown no increase in early 
or late toxicity, and has been shown to improve tumor 
control  and  disease  stabilization26.  In  terms  of  the 
disease  burden,  there  was  no  significant  difference 
between the number of patients with high bulk liver 
involvement (50%) and low bulk patients (50%). 
It  is  noteworthy  that  since  In-111  is  a  gamma 
emitter  agent,  in  order  to  perform  the  dosimetry 
studies  and  also  for  imaging  purposes,  unlike  the 
Y-90- a pure beta emitter-, we do not need a surro-
gating agent; hence, therapy, dosimetry and imaging 
is done using the same agent. This is one of the ad-
vantages of the in-111 therapy which provides an ease 
in  performing  the  peptide  receptor  radionuclide 
therapy. 
Quality  of  life  (QOL)  is  an  important  issue  in 
cancer therapy. Previously, Khan et al.27 investigated 
QOL and symptoms after Lu-177 octreotate therapy in 
patients  with  inoperable  or  metastasized  gastroen-
teropancreatic  or  bronchial  neuroendocrine  tumors 
(NETs). The study looked at differences of at least 10 
points  in  global  health  status  (GHS)/QOL  scores, 
symptom scores, and Karnofsky performance scores 
(KPS)  before  and  after  therapy.  They  realized  that 
regardless of the treatment outcome, patients’ quality 
of life including insomnia, appetite loss, and diarrhea 
improved  significantly.  Similarly,  Teunissen  et  al.28 
evaluated the results of self-assessment questionnaire 
filled  by  patients  after  they  received  Lu-177 
DOTATATE therapy. Kwekkeboom et al 29, 30 showed 
that  other  radionuclide  materials  including  Indi-
um-111 and Y-90 are able to improve the QOL of pa-Theranostics 2012, 2(5) 
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tients in a similar manner. Our study revealed signif-
icant  improvement  in  social,  family,  emotional  and 
functional aspects of patient life and supports previ-
ous studies.   
 
 
 
Figure 2. A 56 year old female patient with pancreatic neuroendocrine cancer with partial response to therapy in liver after two cycles 
of high activity In-111 Pentetreotide; Octreoscan (top) and F-18 FDG PET-CT scans (below) comparing pre and post therapy images. 
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CONCLUSION 
Our  findings  demonstrate  that  high-activity 
In-111 Pentetreotide therapy is a safe, effective ther-
apy  for  patients  with  disseminated  neuroendocrine 
tumors. Our results  suggest that the  long-term tox-
icity profile of this agent is excellent, with no major 
hematological,  renal  or  liver  toxicity  observed.  The 
absence of renal toxicity at cumulative dose up to 2000 
mCi (74 GBq) suggests that maximal tolerated renal 
doses have not been reached.  
While the observed radiological responses were 
mostly  disease  stabilization  by  the  RECIST  criteria 
rather than marked disease regression, this treatment 
regimen has a clear survival benefit as compared to 
historical  data  with  limited  toxicity.  In  our  study, 
survival time was increased in patients who received 
three cycles of therapy compared to those who had 
two  cycles  of  therapy.  The  greatest  survival  times 
following  therapy  were  observed  for  patients  with 
islet cell tumors. Tumors originating in the pancreas 
have been reported to have very high expression of 
somatostatin receptors and we speculate that this may 
increase  the  cellular  uptake  of  the  radiotracer  and 
consequently improve the effectiveness of the radio-
labeled  peptide.  Survival  times  were  significantly 
lower in patients who had multiple sites of metastasis 
compared to  those who  had metastasis at  only one 
site. This is most likely due to higher disease burden 
at the start of treatment and suggests that response 
rates may be greater for patients with mid-stage dis-
ease rather than those with very late stage disease.  
There  is  an  increase,  although  not  statistically 
significant, in survival time in patients with less than 
50% of their liver involved compared to patients with 
more  than  half  hepatic  involvement.  Pretreatment 
FDG status may be a predictor of survival following 
In-111 pentetreotide therapy. 
Hormonal evaluation was performed in patients 
who had three or more cycles of therapy, but due to a 
small sample size no statistically significant difference 
was seen in tumor marker levels before and after the 
therapy session. 
The non-randomized nature of our study is the 
primary limitation and a randomized clinical trial will 
be required to determine if multiple cycles of therapy 
can  increase  survival  times.  Moreover,  due  to  the 
small population, survival advantages for NETs other 
than carcinoid and islet cell tumors could not be de-
termined. 
Competing Interests 
The  authors  have  declared  that  no  competing 
interest exists. 
References 
1.  Raut CP, Kulke MH, Glickman JN, et al. Carcinoid tumors. Curr 
Probl Surg. 2006 Jun;43(6):383-450 
2.  Yao JC, Hassan M, Phan A, et al. One hundred years after "car-
cinoid": epidemiology of and prognostic factors for neuroendocrine 
tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 
20;26(18):3063-72 
3.  Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neu-
roendocrinology 2004; 80 (Suppl 1):3-7 
4.  Arnold  R,  Simon  B,  Wied M. Treatment  of  neuroendocrine  GEP 
tumours with somatostatin analogues: a review. Digestion 2000; 62 
(Suppl 1):84-91. 
5.  Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somato-
statin analogue DOTA-NOC in patients with neuroendocrine tu-
mors: characterization of uptake in normal organs and tumor le-
sions. Q J Nucl Med Mol Imaging. 2010 Feb; 54(1):61-7. 
6.  Stokkel MP, Boot IN, Smit JW. Personal dosimetry of the staff dur-
ing treatment of neuroendocrine tumours with a high dose of In-
dium-111 Octreotide. Q J Nucl Med. 2002 Dec; 46(4):331-5. 
7.  Krenning  EP,  Kooij  PP,  Bakker  WH,  et  al.  Radiotherapy  with  a 
radiolabeled  somatostatin  analogue,  [111In- 
DTPA-D-Phe1]-octreotide. A case history. Ann NY Acad Sci 1994; 
733:496-506. 
8.  Krenning  EP,  Kooij  PP,  Pauwels  S,  et  al.  Somatostatin  receptor: 
scintigraphy  and  radionuclide  therapy.  Digestion. 1996;  57(Suppl 
1):57-61. 
9.  Haselkorn  T,  Whittemore  AS,  Lilienfeld  DE.  Incidence  of  small 
bowel  cancer  in  the  United  States  and  worldwide:  geographic, 
temporal,  and  racial  differences.  Cancer  Causes  Control  2005; 
16:781-7. 
10.  Buscombe  JR,  Caplin  ME,  Hilson  AJ.  Long-term  efficacy  of 
high-activity 111in-pentetreotide therapy in patients with dissemi-
nated neuroendocrine tumors. J Nucl Med 2003; 44:1-6. 
11.  De  Jong  M,  Valkema  R,  Jamar  F,  et  al.  Somatostatin  recep-
tor-targeted radionuclide therapy of tumors: preclinical and clinical 
findings. Semin Nucl Med 2002; 32:133-40. 
12.  Fjalling M, Andersson P, Forssell-Aronsson E, et al. Systemic radi-
onuclide  therapy  using  indium-111-DTPA-D-Phe1-octreotide  in 
midgut carcinoid syndrome. J Nucl Med 1996;37:1519-21. 
13.  McCarthy KE, Woltering EA, Espenan GD, et al. In situ radiother-
apy with 111In-pentetreotide: initial observations and future direc-
tions. Cancer J Sci Am 1998; 4:94-102. 
14.  Meyers MO, Anthony LB, McCarthy KE, et al. High dose indium 
111In pentetreotide radiotherapy for metastatic atypical carcinoid 
tumor. South Med J 2000; 93: 809-11. 
15.  Nguyen  C,  Faraggi M,  Giraudet  AL,  et al.  Long-term  efficacy  of 
radionuclide therapy in patients with disseminated neuroendocrine 
tumors  uncontrolled  by  conventional  therapy.  J  Nucl  Med  2004; 
45:1660-8. 
16.  Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of 
radionuclide therapy with high-activity In-111 pentetreotide in pa-
tients with progressive neuroendocrine tumors. Cancer Biotherapy & 
Radiopharmaceuticals. 2008; 23: 292-300. 
17.  Stabin  MG,  Sparks  RB,  Crowe  E.  OLINDA/EXM:  the  se-
cond-generation personal computer software for internal dose as-
sessment in nuclear medicine. J Nucl Med 2005; 46:1023-7. 
18.  Anthony  LB,  Woltering  EA,  Espenan  GD,  et  al.  Indi-
um-111-pentetreotide prolongs  survival  in gastroenteropancreatic 
malignancies. Seminars in Nuclear Medicine. 2002 Apr;32(2):123-32 
19.  Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of 
Results of Peptide Receptor Radionuclide Therapy with 3 Radio-
labeled Somatostatin Analogs. J Nucl Med 2005; 46:62S–66S. 
20.  Waldherr  C,  Pless  M,  Maecke  HR,  et  al.  The  clinical  value  of 
[90Y-DOTA]-D-Phe1-Tyr3-octreotide  (90Y-DOTATOC)  in  the 
treatment of neuroendocrine tumours: a clinical phase II study. Ann 
Oncol. 2001; 12:941–5. 
21.  Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical 
benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J 
Nucl Med. 2002; 43:610–6. 
22.  Waldherr C, Schumacher T, Maecke HR, et al. Does tumor response 
depend on the number of treatment sessions at constant injected Theranostics 2012, 2(5) 
 
http://www.thno.org 
480 
dose using 90yttrium-DOTATOC in neuroendocrine tumors? Eur J 
Nucl Med. 2002; 29 (suppl):S100. 
23.  Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the 
radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: 
Toxicity,  efficacy,  and  survival.  J  Clin  Oncol  2008  May 
1;26(13):2124-30 
24.  Forrer,  F.,  Uusijarvi,  H.,  Storch,  D.,  et  al.  Treatment  with 
177Lu-DOTATOC of patients with relapse of neuroendocrine tu-
mors after treatment with 90Y-DOTATOC. J Nucl Med. 2005 Aug; 
46(8):1310-6. 
25.  Hubble D, Kong G, Michael M et al. 177Lu-octreotate, alone or with 
radiosensitising chemotherapy, is safe in neuroendocrine tumour 
patients previously treated with high-activity 111In-octreotide. Eur J 
Nucl Med Mol Imaging 2010; 37:1869–75. 
26.  Claringbold PG, Brayshaw PA, Price RA, et al. Phase II study of 
radiopeptide  177Lu-octreotate  and  capecitabine  therapy  of  pro-
gressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol 
Imaging, 2011 Feb; 38(2):302-11. 
27.  Khan S, Krenning EP, van Essen M,, et al: Quality of life in 265 
patients  with  gastroenteropancreatic  tumours  or  bronchial  car-
cinoids treated with [177Lu-DOTA0, Tyr3] octreotate. J Nucl Med. 
2011 Sep; 52(9):1361-8.  
28.  Teunissen JJ, Kwekkeboom DJ, Krenning EP: Quality of life in pa-
tients  with  gastroenteropancreatic  tumors  treated  with 
[177Lu-DOTA0,  Tyr3]  octreotate.  J  Clin  Oncol  2004  Jul 
1;22(13):2724-9. 
29.   Kwekkeboom  DJ,  de  Herder WW,  van  Eijck CH, Kam  BL, van 
Essen M, Teunissen JJ, Krenning EP: Peptide receptor radionuclide 
therapy  in  patients  with  gastroenteropancreatic  neuroendocrine 
tumors. Semin Nucl Med 2010 Mar; 40 (2):78-88 
30.   Kwekkeboom  DJ,  Kam  BL,  van  Essen  M,  et  al.  Somatosta-
tin-receptor-based imaging and therapy of gastroenteropancreatic 
neuroendocrine  tumors.  Endocr  Relat  Cancer.  2010  Jan  29; 
17(1):R53-73. 